Regulation of Topisomerase I activity by cMet in lung cancer
Project/Area Number |
26430159
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Tumor therapeutics
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
曽根 崇 金沢大学, 医薬保健学総合研究科, 特任准教授 (30420334)
木村 英晴 金沢大学, 医学系, 助教 (40444202)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | cMet / Topoisomerase I / Lung cancer / 肺癌 / MET遺伝子 / Toppisomerase I |
Outline of Final Research Achievements |
We examined the relationship between cMet and Topoisomerase I lung cancer. Protein expression and phosphorylation of cMet using 10 lung cancer cell lines revealed high expression and hyperphosphorylation in 5 cell line.Expression and activity of Topo I were higher in cMet overexpressing cells and were related to the sensitivity of Topo I inhibitors. Inhibition of cMet by Met inhibitor also decreased Topo I. Upon examination of the downstream signaling, 29 candidate genes associated with Topo I expression were identified by cMet stimulation and suppression. In analysis using clinical donation, cMet nominated positive with 37.7% and TopoI at 51.3%, showing a significant correlation. This study suggests that cMet may regulate the expression of Topo I and we believe that it will bring important findings to establish future treatment strategies
|
Report
(4 results)
Research Products
(11 results)
-
-
[Journal Article] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.2016
Author(s)
Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.
-
Journal Title
ESMO Open.
Volume: 1
Issue: 4
Pages: 1-6
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
[Journal Article] Pleuroparenchymal fibroelastosis: Distinct pulmonary physiological features in nine patients2015
Author(s)
Watanabe, S. Waseda, Y. Takato, H. Matsunuma, R. Johkoh, T. Egashira, R. Kawabata, Y. Ikeda, H. Yasui, M. Fujimura, M. Kasahara, K.
-
Journal Title
Respir Investig
Volume: 53
Issue: 4
Pages: 149-155
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
[Journal Article] (18)F-Fdg Uptake Predicts Diagnostic Yield of Transbronchial Biopsy in Peripheral Lung Cancer.2014
Author(s)
6.Umeda, Y., Y. Demura, M. Anzai, H. Matsuoka, T. Araya, M. Nishitsuji, K. Nishi, T. Tsuchida, Y. Sumida, M. Morikawa, S. Ameshima, T. Ishizaki, K. Kasahara, and T. Ishizuka.
-
Journal Title
Lung Cancer
Volume: 85
Issue: 1
Pages: 47-52
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Efficacy and Safety of Weekly Nab-Paclitaxel Plus Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer."2014
Author(s)
5.Satouchi, M., I. Okamoto, H. Sakai, N. Yamamoto, Y. Ichinose, H. Ohmatsu, N. Nogami, K. Takeda, T. Mitsudomi, K. Kasahara, and S. Negoro.
-
Journal Title
Lung Cancer
Volume: 81
Issue: 2
Pages: 97-101
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Presentation] Retrospective analysis of prognostic factors in non-small cell lung cancer with EGFR mutations.2014
Author(s)
Shingo Nishikawa, Takashi Sone, Taro Yoneda, Kazuhiko Shibata, Koji Kurokawa, Toshiyuki Kita, Hiroki Shirasaki, Kazuyoshi Watanabe, Hideharu Kimura, Kazuo Kasahara
Organizer
2014 ASCO Annual Meeting
Place of Presentation
Mccormick Place Chicago,USA
Year and Date
2014-05-30 – 2014-06-03
Related Report
-
[Presentation] Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy2014
Author(s)
Tomonori Hirashima, Koichi Azuma, Nobuyuki Yamamoto, Toshiaki Takahashi, Makoto Nishio, Taizo Hirata, Kaoru Kubota, Kazuo Kasahara, Toyoaki Hida, Hiroshige Yoshioka, Kohei Suzuki, Shiro Akinaga, Kazuto Nishio, Tetsuya Mitsudomi, Kazuhiko Nakagawa
Organizer
2014 ASCO Annual Meeting
Place of Presentation
Mccormick Place Chicago,USA
Year and Date
2014-05-30 – 2014-06-03
Related Report